Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds

More articles from Clinical

  • You have access
    PSMA Theranostics: Is the Time Ripe to Pave the Way to Further Tumor Entities?
    Winfried Brenner, Joachim Strobel and Vikas Prasad
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1242-1243; DOI: https://doi.org/10.2967/jnumed.121.262737
  • Head-to-Head Comparison of <sup>68</sup>Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients
    Open Access
    Head-to-Head Comparison of 68Ga-Prostate-Specific Membrane Antigen PET/CT and Ferumoxtran-10–Enhanced MRI for the Diagnosis of Lymph Node Metastases in Prostate Cancer Patients
    Melline G.M. Schilham, Patrik Zamecnik, Bastiaan M. Privé, Bas Israël, Mark Rijpkema, Tom Scheenen, Jelle O. Barentsz, James Nagarajah and Martin Gotthardt
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1258-1263; DOI: https://doi.org/10.2967/jnumed.120.258541
  • Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study
    You have access
    Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study
    Caroline Bodet-Milin, Alain Faivre-Chauvet, Thomas Carlier, Catherine Ansquer, Aurore Rauscher, Eric Frampas, Frederique Toulgoat, Damien Masson, Mickael Bourgeois, Evelyne Cerato, Vincent Rohmer, Olivier Couturier, Delphine Drui, David M. Goldenberg, Robert M. Sharkey, Jacques Barbet and Francoise Kraeber-Bodere
    Journal of Nuclear Medicine September 1, 2021, 62 (9) 1221-1227; DOI: https://doi.org/10.2967/jnumed.120.252791
  • Toward a Universal Readout for <sup>18</sup>F-Labeled Amyloid Tracers: The CAPTAINs Study
    You have access
    Toward a Universal Readout for 18F-Labeled Amyloid Tracers: The CAPTAINs Study
    Gérard N. Bischof, Peter Bartenstein, Henryk Barthel, Bart van Berckel, Vincent Doré, Thilo van Eimeren, Norman Foster, Jochen Hammes, Adriaan A. Lammertsma, Satoshi Minoshima, Chris Rowe, Osama Sabri, John Seibyl, Koen Van Laere, Rik Vandenberghe, Victor Villemagne, Igor Yakushev and Alexander Drzezga
    Journal of Nuclear Medicine July 1, 2021, 62 (7) 999-1005; DOI: https://doi.org/10.2967/jnumed.120.250290
  • You have access
    Early Treatment Response Assessment Using 18F-FET PET Compared with Contrast-Enhanced MRI in Glioma Patients After Adjuvant Temozolomide Chemotherapy
    Garry Ceccon, Philipp Lohmann, Jan-Michael Werner, Caroline Tscherpel, Veronika Dunkl, Gabriele Stoffels, Jurij Rosen, Marion Rapp, Michael Sabel, Ulrich Herrlinger, Niklas Schäfer, Nadim J. Shah, Gereon R. Fink, Karl-Josef Langen and Norbert Galldiks
    Journal of Nuclear Medicine July 1, 2021, 62 (7) 918-925; DOI: https://doi.org/10.2967/jnumed.120.254243
  • Cardiac β-Adrenergic Receptor Downregulation, Evaluated by Cardiac PET, in Chronotropic Incompetence
    You have access
    Cardiac β-Adrenergic Receptor Downregulation, Evaluated by Cardiac PET, in Chronotropic Incompetence
    Toshihiko Goto, Shohei Kikuchi, Kento Mori, Takafumi Nakayama, Hidekatsu Fukuta, Yoshihiro Seo, Hitomi Narita, Akihiko Iida and Nobuyuki Ohte
    Journal of Nuclear Medicine July 1, 2021, 62 (7) 996-998; DOI: https://doi.org/10.2967/jnumed.120.253419
  • First Experiences with <sup>177</sup>Lu-PSMA Therapy in Combination with Pembrolizumab or After Pretreatment with Olaparib in Single Patients
    You have access
    First Experiences with 177Lu-PSMA Therapy in Combination with Pembrolizumab or After Pretreatment with Olaparib in Single Patients
    Vikas Prasad, Friedemann Zengerling, Jochen P. Steinacker, Christian Bolenz, Meinrad Beer, Thomas Wiegel, Matthias Eiber, Neil Fleshner and Ambros J. Beer
    Journal of Nuclear Medicine July 1, 2021, 62 (7) 975-978; DOI: https://doi.org/10.2967/jnumed.120.249029
  • <sup>11</sup>C-Sorafenib and <sup>15</sup>O-H<sub>2</sub>O PET for Early Evaluation of Sorafenib Therapy
    You have access
    11C-Sorafenib and 15O-H2O PET for Early Evaluation of Sorafenib Therapy
    Lemonitsa H. Mammatas, Maqsood Yaqub, N. Harry Hendrikse, Otto S. Hoekstra, Richard J. Honeywell, Robert C. Schuit, Martijn Meijerink, Lothar A. Schwarte, Godefridus J. Peters, Henk M.W. Verheul, Adriaan A. Lammertsma and C. Willemien Menke-van der Houven van Oordt
    Journal of Nuclear Medicine July 1, 2021, 62 (7) 934-940; DOI: https://doi.org/10.2967/jnumed.120.251611
  • Positive Predictive Value and Correct Detection Rate of <sup>18</sup>F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard
    You have access
    Positive Predictive Value and Correct Detection Rate of 18F-rhPSMA-7 PET in Biochemically Recurrent Prostate Cancer Validated by Composite Reference Standard
    Maythinee Chantadisai, Gabriel Buschner, Markus Krönke, Isabel Rauscher, Thomas Langbein, Stephan G. Nekolla, Kilian Schiller, Matthias M. Heck, Tobias Maurer, Alexander Wurzer, Hans-Juergen Wester, Calogero D’Alessandria, Wolfgang Weber and Matthias Eiber
    Journal of Nuclear Medicine July 1, 2021, 62 (7) 968-974; DOI: https://doi.org/10.2967/jnumed.120.255661
  • Feasibility of Single-Time-Point Dosimetry for Radiopharmaceutical Therapies
    You have access
    Feasibility of Single-Time-Point Dosimetry for Radiopharmaceutical Therapies
    Xinchi Hou, Julia Brosch, Carlos Uribe, Alessandro Desy, Guido Böning, Jean-Mathieu Beauregard, Anna Celler and Arman Rahmim
    Journal of Nuclear Medicine July 1, 2021, 62 (7) 1006-1011; DOI: https://doi.org/10.2967/jnumed.120.254656

Pages

  • Previous
  • Next
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • 62
SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire